Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The consumption of dietary salt (NaCl) is controlled by neuronal pathways that are modulated by endogenous opioid signalling. The latter is disrupted by chronic use of exogenous opioid receptor agonists, such as morphine. Therefore, opioid dependence may influence salt consumption, which we investigated in two complimentary studies in humans and mice.
Methods: Human study: three groups were recruited: i. Individuals who are currently opioid dependent and receiving opioid substitution treatment (OST); ii. Previously opioid dependent individuals, who are currently abstinent, and; iii. Healthy controls with no history of opioid dependence. Participants tasted solutions containing different salt concentrations and indicated levels of salt 'desire', salt 'liking', and perceptions of 'saltiness'. Mouse study: preference for 0.1 M versus 0.2 M NaCl and overall levels of salt consumption were recorded during and after chronic escalating morphine treatment.
Results: Human study: Abstinent participants' 'desire' for and 'liking' of salt was shifted towards more highly concentrated salt solutions relative to control and OST individuals. Mouse study: Mice increased their total salt consumption during morphine treatment relative to vehicle controls, which persisted for 3 days after cessation of treatment. Preference for 'low' versus 'high' concentrations of salt were unchanged.
Conclusion: These findings suggest a possible common mechanistic cross-sensitization to salt that is present in both mice and humans and builds our understanding of how opioid dependence can influence dietary salt consumption. This research may help inform better strategies to improve the diet and overall wellbeing of the growing number of individuals who develop opioid dependence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drugalcdep.2019.05.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting G9a decreases escalated alcohol drinking in male mice in a model of combined stress and chronic alcohol exposure.
Alcohol Clin Exp Res (Hoboken)
September 2025
Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, USA.
Background: Alcohol use disorder (AUD) is a pervasive problem in society afflicting millions of people worldwide. One reason for the prevalence of AUD is that heavy alcohol drinking can produce alcohol dependence. In addition, alcohol dependence dysregulates the body's stress systems to increase alcohol drinking.
View Article and Find Full Text PDFOpioid agonist therapy for opioid use disorder in primary versus specialty care.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFOptimizing care transitions to post-acute care following hospitalization for people with opioid use disorder.
Innov Aging
August 2025
Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, United States.
Background And Objectives: Increased referrals to skilled nursing facilities (SNFs) from hospitalized people with opioid use disorder (OUD) carry risk for financial, safety, and legal consequences for poor transitions in care. We aimed to better understand the hospital to SNF referral process and identify opportunities to improve transitions and care for people with OUD, an increasing share of whom are older adults.
Research Design And Methods: Participants included administrative, executive leadership, and clinical staff involved in SNF admission decisions across the United States.
Buprenorphine maintenance treatment and its outcome among opioid dependent pregnant women: A case series from India.
Indian J Psychiatry
August 2025
National Drug Dependence Treatment Centre, AIIMS, New Delhi, India.
Perinatal opioid use is the major public health concern worldwide due to its hazardous effect on the mother and the developing fetus. Opioid agonist maintenance treatment with buprenorphine or methadone has been the recommended treatment for opioid dependence during pregnancy for various reasons. There is scarcity of literature in this regard.
View Article and Find Full Text PDFRelationship Between State Policies Targeting Unethical Treatment Practices and Opioid-Related Outcomes: An Event Study Analysis.
Subst Use Addctn J
October 2025
Partnered Evidence-based Policy Resource Center, Boston VA Healthcare System, Boston, MA, USA.
Objectives: To estimate the effect of the passage of state laws targeting patient brokering on opioid-related outcomes.
Background: In response to growing awareness of unethical substance use disorder (SUD) treatment practices, several states in the United States have passed laws targeting patient brokering and deceptive marketing. Patient brokering and deceptive marketing laws are intended to reduce the chances individuals with SUD interact with bad actors or suffer from adverse outcomes related to inappropriate SUD treatment, but the effectiveness of these laws is unknown.